Our Pipeline

Small molecules. Validated targets. Clear paths to patients.

KeifeRx is advancing a second generation of orally delivered small molecules that demonstrate high blood-brain-barrier penetration and selective kinase inhibition resulting in increased toxic protein clearance, reduced inflammation and vascular repair in multiple neurodegenerative diseases.

KFRX03

Alzheimer's Disease

  1. 01Discovery
  2. 02Lead Optimization
  3. 03IND-enabling
  4. 04Phase 1

Targetsc-ABL, c-KIT, DDR-1

StatusPhase 1 Patient Enrollment 2026

KFRX04

ALS

  1. 01Discovery
  2. 02Lead Optimization
  3. 03IND-enabling
  4. 04Phase 1

Targetsc-KIT, PIKfyve

StatusExploring Co-development Opportunities

KFRX05

Parkinson's Disease

  1. 01Discovery
  2. 02Lead Optimization
  3. 03IND-enabling
  4. 04Phase 1

Targetsc-ABL, c-KIT (mutants)

StatusExploring Co-development Opportunities

KFRX06

Parkinson's DiseaseFrontotemporal Dementia

  1. 01Discovery
  2. 02Lead Optimization
  3. 03IND-enabling
  4. 04Phase 1

TargetsLRRK2, c-ABL, c-KIT

StatusExploring Co-development Opportunities